Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2803-2810

  Specht, Jennifer M ^a   Kurland, Brenda F ^b   Montgomery, Susan K ^a   Dunnwald, Lisa K ^a   Doot, Robert K ^a   Gralow, Julie R ^a   Ellis, Georgina K ^a   Linden, Hannah M ^a   Livingston, Robert B ^c   Allison, Kimberly H ^a   Schubert, Erin K ^a   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METABOLISM; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BLOOD FLOW;

ADULT; AGED; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77952350449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0026     Document Type: Article

References (36)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-752
2. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene Expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874 (Pubitemid 32878711)
4. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685 (Pubitemid 41170290)
5. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423 (Pubitemid 36842560)
6. Cleater S, Heller W, Coombes R. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-244 (Pubitemid 46291713)
7. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281
8. Keam B, Im S-A, Kim H-J, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007:7. (Pubitemid 351193977)
9. Dunnwald LA, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008; 26:4449-4457
10. Mankoff DA, Dunnwald LA, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-509
11. Mankoff DA, Dunnwald LA, Gralow JR, et al. Change in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-1814 (Pubitemid 39663314)
12. Mankoff DA, Dunnwald LA, Partridge SC, Specht JM. Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient: commentary on Komar et al., p. 5511. Clin Cancer Res 2009;15:5294-6.
13. Komar G, Kauhanen KL, Seppanen M, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009;15:5511-5517
14. Eby P, Partridge SC, White S. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246-1254
15. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;25:786-790 (Pubitemid 351264392)
16. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-2581
17. McCready D, Hortobagyi G, Kau S, Smith T, Buzdar A, Balch C. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989; 124:21-25 (Pubitemid 19025896)
18. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008;8:81-86
19. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor positive/HER2-negative breast carcinoma using quantitative fluorine-18 flurodeoxyglucose/positron emission tomography imaging parameters. Cancer 2007;112:995-1000.
20. Sobin L, Fleming I. TNM classification of malignant tumors, fifth edition (1997): union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804
21. Sobin L, Wittekind C. TNM Classification of Malignant Tumors, 6th edition: International Union Against Cancer. 6th ed New York: Wiley-Liss; 2002.
22. Hamacher K, Coenen H, Stocklin G. Efficient stereospecific synthesis of no-carrier added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substition. J Nucl Med 1986;27:235-238 (Pubitemid 17024868)
23. Lewellen T, Kohmyer S, Miyaoka R. Investigation of the count rate performance of the General Electric ADVANCE positron emission tomograph. IEEE Trans Nucl Sci 1995;42:1051-1057
24. Tseng J, Dunnwald LA, Schubert EK, et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004;45:1829-1837
25. Tune JD, Gorman MW, Feigl EO. Matching coronary blood flow to myocardial oxygen consumption. J Appl Physiol 2004;97:404-415
26. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005;19:7-16.
27. Thompson CB, Bauer DE, Lum JJ, et al. How do cancer cells acquire the fuel needed to support cell growth? Cold Spring Harb Symp Quant Biol 2005;70:357-362
28. Mallepel S, Krust A, Chambon P, et al. Paracrine signaling through the epithelial estrogen receptor α is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A 2006;103:2196-2201
29. Nandi S. Endocrine control of the mammary gland development and function in the C3H/H3 Crgl mouse. J Natl Cancer Inst 1958;21: 1039-1063
30. Schelbert HR. PET contribution to understanding normal and abnormal cardiac perfusion and metabolism. Ann Biomed Eng 2000;28: 922-929
31. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009;39:36-51.
32. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005;43:121-134
33. Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 2008;5:149-159
34. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27: 1160-1167
35. Krak N, van der Hoeven J, Hoekstra O, et al. Blood flow and glucose metabolism in stage IV breast cancer; heterogeneity of response during chemotherapy. Mol Imaging Biol 2008;10:356-363
36. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide followed by weekly taclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally-advanced breast cancer. J Clin Oncol 2006;24:LBA 537.